Brandt, Jaden

Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research

Brandt, J., & Leong, C. (2017) · Drugs in R&D

Pharmaceutical Practices and Patient OutcomesSubstance Abuse Treatment and Outcomes

Cited by 356

Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review

Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine

Pharmaceutical Practices and Patient OutcomesAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 77

Translating benzodiazepine utilization data into meaningful population exposure: integration of two metrics for improved reporting

Brandt, J., Alkabanni, W., Alessi-Severini, S., & Leong, C. (2018) · Clinical Drug Investigation

Pharmaceutical Practices and Patient OutcomesPharmaceutical studies and practices

Cited by 27

The devil is in the detail: a critique of nine editorials published by the International Task Force on Benzodiazepines

Brandt, J. (2024) · BJPsych Advances

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

Cited by 3

Pharmacological principles for safe benzodiazepine and Z-drug dose reduction

Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine

Pharmaceutical Practices and Patient OutcomesSubstance Abuse Treatment and Outcomes

Cited by 0